Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
- 主要终点
- Recurrence-free survival
研究概览
简要总结
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.
详细描述
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cervical cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer.
- •they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer).
排除标准
- •studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.
研究组 & 干预措施
RFA alone
Patients undergo radiofrequency ablation alone.
RFA+CIK
Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
干预措施: Radiofrequency ablation (Procedure)
RFA+CIK
Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
干预措施: Cytokine-induced killer cells (Biological)
结局指标
主要结局
Recurrence-free survival
时间窗: 1 year
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
次要结局
未报告次要终点